Eli Lilly Expands Its In Vivo Ambitions, Acquiring Cell Therapy Startup Orna for up to $2.4B / MedCity

Frank Vinluan / medcitynews - Orna Therapeutics brings Eli Lilly an in vivo cell therapy ready for Phase 1 testing as a potential treatment for autoimmune diseases. Lilly is now the latest pharma company to use M&A to enter this growing field, following deals made in the past year by …

#healthcare #pharmaceuticals #elililly #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment


Saturday, February 14, 2026, 3:21 am / permalink 19178 / 9 stories in 25 days



Related Stories




Related Tags



StackHealth Time Machine





NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.